More than 400 students celebrated a milestone on May 19: graduating from Weill Cornell Medical College and Weill Cornell Graduate School of Medical Sciences.
The award recognizes alumni for their outstanding contributions to biomedical research in education, focusing on science and scholarship, leadership, mentoring and teaching, and service to society.
A protein called CDC7, long thought to play an essential role early in the cell division process, is in fact replaceable by another protein called CDK1, according to a study by investigators at Weill Cornell Medicine and the Dana-Farber Cancer Institute.
Using cutting-edge techniques, Weill Cornell Medicine and Memorial Sloan Kettering investigators have visualized the structure of a receptor targeted by an anti-cancer immunotherapy.
Two multi-institutional teams led by Weill Cornell Medicine scientists have been awarded grant support from the Starr Cancer Consortium. Both grants will fund work applying new technologies to develop more detailed knowledge of tumor biology, with one team focusing on Hodgkin lymphoma and the other on the purity of tumor samples on pathology slides.
Investigators from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center have discovered how a drug for multiple sclerosis interacts with its targets, a finding that may pave the way for better treatments.
Two Weill Cornell Medicine physician-scientists, Dr. Randy Longman and Dr. Robert Schwartz, have been elected as members of the American Society for Clinical Investigation.
Scientists at the Jill Roberts Institute for Research in Inflammatory Bowel Disease at Weill Cornell Medicine have developed a pipeline that enables genetic manipulation of nonmodel gut bacteria.
A protein that masterminds the way DNA is wrapped within chromosomes has a major role in the healthy functioning of blood stem cells, which produce all blood cells in the body, according to a new study from researchers at Weill Cornell Medicine.
Investigators at Weill Cornell Medicine have identified significant differences in the molecular characteristics of tumors from younger and older cancer patients across several cancer types.
A group of immune cells that normally protect against inflammation in the gastrointestinal tract may have the opposite effect in multiple sclerosis (MS) and other brain inflammation-related conditions, according to a new study by Weill Cornell Medicine and NewYork-Presbyterian researchers.
Antibody protection against harmful forms of fungi in the gut may be disrupted in some patients with Crohn’s disease—a condition caused by chronic inflammation in the bowel—according to a new study by Weill Cornell Medicine investigators.
COVID-19 may bring high risks of severe disease and death in many patients by disrupting key metabolic signals and thereby triggering hyperglycemia, according to a new study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.
The master regulator behind the development of antibody-producing cells has been identified in a study by investigators at Weill Cornell Medicine. The findings provide new insight into the inner workings of the immune system and may help understand how tissues develop and how certain cancers arise.
Weill Cornell Medicine has been awarded a five-year, $28.5 million Martin Delaney Collaboratory grant from the National Institutes of Health to lead a multi-institutional effort aimed at finding a cure for HIV.
A better understanding of the biology of tuberculosis (TB) infection and improved drug combinations for the disease are two areas of research in which the TB Drug Accelerator (TBDA) has made strides since its inception a decade ago.
